A New Vision
For ophthalmic drug delivery.
Our innovative injector enables ophthalmologists
to perform in-office Suprachoroidal drug administration,
for safe, effective, and long-lasting treatments for various eye conditions.
Embedded Files
A Noval Approach
A Noval Approach
The suprachoroidal approach is a novel drug delivery route that improves outcomes for a wide variety of treatments and paves the way for groundbreaking gene therapies.
Our innovative injection system makes this approach easily applicable, delivering better vision and quality of life for patients.
The Problem
The Problem
With growing life expectancy, the number of treatments required for eye diseases (i.e. AMD, DR, RP, Uveitis, etc.) is already rising
and is expected to grow immensely within the next decade.
Currently, treatments for most of these diseases are commonly done by administering drugs targeting the posterior segment of the eye.
Intravitreal
Intravitreal
Easy to administer in an office setting, but has limited effectiveness. Often require frequent dosing, and can result in substantial side effects, additionally, they are unsuitable for gene therapies.
Subretinal
Subretinal
Reduced immune reactions for gene therapy, but their effects are confined to injection sites and they are challenging and invasive, and thus can only be done by highly skilled ophthalmologists in the OR.
The Challenge
The Challenge
The suprachoroidal space is a thin, expandable space between the sclera and choroid, and an attractive site for drug delivery.
But there is a challenge: The needle bevel at over 1 mm,
cannot fit inside the Choroid layer at about 0.1 mm...
The Solution
The Solution
Switching from a perpendicular to a tangent approach, mitigated the risk of penetrating the vitreous, alleviated the need to apply force to the eye, and minimized drug loss due to reflux by forming a natural seal post-injection.
The Benefits
The Benefits
The Supra SEG is a single-use suprachoroidal injector designed to deliver medications to the posterior segment of the eye
in an in-office procedure.
Safe by design:
The innovative approach reduces the risks associated with subretinal and intravitreal injections.
Precision engineering: Ensures accurate dosing with minimal reflux, for optimal treatment.
Patient comfort: Minimize the force applied to the eye, reducing patient discomfort.
Minimal training: The intuitive design, requires minimal training and enables a fast adaptation
Report abuse